Squarepoint’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $16.4M | Buy |
65,300
+9,700
| +17% | +$2.09M | 0.02% | 797 |
|
|
2026
Q1 | $12.1M | Sell |
55,600
-93,100
| -63% | -$20.7M | 0.01% | 975 |
|
|
2025
Q4 | $34M | Buy |
148,700
+60,000
| +68% | +$13.7M | 0.04% | 540 |
|
|
2025
Q3 | $20.5M | Sell |
88,700
-126,200
| -59% | -$25.7M | 0.02% | 732 |
|
|
2025
Q2 | $39.9M | Sell |
214,900
-43,000
| -17% | -$7.99M | 0.04% | 464 |
|
|
2025
Q1 | $54M | Buy |
257,900
+40,500
| +19% | +$7.87M | 0.07% | 324 |
|
|
2024
Q4 | $38.6M | Buy |
217,400
+100,800
| +86% | +$18.5M | 0.04% | 472 |
|
|
2024
Q3 | $23M | Sell |
116,600
-3,900
| -3% | -$728K | 0.04% | 534 |
|
|
2024
Q2 | $20.7M | Sell |
120,500
-263,800
| -69% | -$43.7M | 0.03% | 566 |
|
|
2024
Q1 | $70M | Buy |
384,300
+268,200
| +231% | +$46.2M | 0.12% | 161 |
|
|
2023
Q4 | $18M | Buy |
116,100
+101,300
| +684% | +$14.8M | 0.03% | 615 |
|
|
2023
Q3 | $2.21M | Sell |
14,800
-15,500
| -51% | -$2.28M | 0.01% | 1735 |
|
|
2023
Q2 | $4.08M | Buy |
30,300
+17,800
| +142% | +$2.61M | 0.01% | 1188 |
|
|
2023
Q1 | $1.99M | Sell |
12,500
-30,000
| -71% | -$4.59M | 0.01% | 1418 |
|
|
2022
Q4 | $6.87M | Buy |
42,500
+32,600
| +329% | +$5M | 0.03% | 675 |
|
|
2022
Q3 | $1.33M | Sell |
9,900
-7,400
| -43% | -$1.06M | 0.01% | 1575 |
|
|
2022
Q2 | $2.65M | Buy |
17,300
+12,200
| +239% | +$1.86M | 0.01% | 1020 |
|
|
2022
Q1 | $827K | Sell |
5,100
-5,600
| -52% | -$813K | ﹤0.01% | 1701 |
|
|
2021
Q4 | $1.45M | Sell |
10,700
-2,500
| -19% | -$295K | ﹤0.01% | 1458 |
|
|
2021
Q3 | $1.42M | Sell |
13,200
-32,000
| -71% | -$3.66M | ﹤0.01% | 1368 |
|
|
2021
Q2 | $5.09M | Sell |
45,200
-9,500
| -17% | -$1.07M | 0.02% | 718 |
|
|
2021
Q1 | $5.92M | Buy |
54,700
+32,900
| +151% | +$3.52M | 0.03% | 557 |
|
|
2020
Q4 | $2.34M | Buy |
21,800
+19,300
| +772% | +$1.85M | 0.02% | 864 |
|
|
2020
Q3 | $219K | Buy |
2,500
+200
| +9% | +$18.8K | ﹤0.01% | 2028 |
|
|
2020
Q2 | $226K | Buy |
+2,300
| New | +$203K | ﹤0.01% | 1764 |
|
|
2020
Q1 | – | Sell |
-2,800
| Closed | -$248K | – | 1793 |
|
|
2019
Q4 | $248K | Sell |
2,800
-12,800
| -82% | -$1.06M | ﹤0.01% | 2127 |
|
|
2019
Q3 | $1.18M | Buy |
15,600
+11,300
| +263% | +$775K | 0.01% | 1111 |
|
|
2019
Q2 | $313K | Buy |
4,300
+200
| +5% | +$15.7K | ﹤0.01% | 1916 |
|
|
2019
Q1 | $330K | Buy |
+4,100
| New | +$335K | ﹤0.01% | 1722 |
|
Other funds holding ABBV
Squarepoint's ABBV Position: Q2 2026 in Review
Squarepoint reduced its AbbVie (ABBV) stake by 53% in Q2 2026, selling an estimated $21.9M and leaving 91,950 shares worth $23.1M. The position accounts for 0.03% of the portfolio, ranked #627.
Squarepoint first reported a position in ABBV in Q3 2015 and has held it in 32 quarters since. The position peaked at $92.1M in Q2 2025. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Squarepoint held 91,950 shares of AbbVie worth $23.1M as of Q2 2026.
- Squarepoint sold 101,921 AbbVie shares in Q2 2026, an estimated $21.9M.
- AbbVie made up 0.03% of Squarepoint's portfolio in Q2 2026, its #627 holding.
- Squarepoint first reported a position in AbbVie in Q3 2015 and has held it in 32 quarters since.
- Squarepoint's AbbVie position peaked at $92.1M in Q2 2025.
- 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.